TransMedics Group (NASDAQ:TMDX) Receives a Downgrade
Research professionals at the BidaskScore equities research division downgraded the rating of TransMedics Group (NASDAQ:TMDX) shares to a Sell on 3 December.
The stock decreased 0.06% or $0.01 during the last trading session, reaching $17.7. About 90,449 shares traded. TransMedics Group, Inc. (NASDAQ:TMDX) has 0.00% since December 5, 2018 and is . It has by 0.00% the S&P500.
Analysts await TransMedics Group, Inc. (NASDAQ:TMDX) to report earnings on February, 5. After $-0.39 actual earnings per share reported by TransMedics Group, Inc. for the previous quarter, Wall Street now forecasts -5.13 % EPS growth.
Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company has market cap of $374.60 million. The firm offers Organ Care System , a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It currently has negative earnings. The Company’s Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers.
More notable recent TransMedics Group, Inc. (NASDAQ:TMDX) news were published by: Globenewswire.com which released: “Final Results from The Heart EXPAND Pivotal Trial Using the Organ Care System (OCS) Heart Technology Presented at the 2019 Annual Meeting of The International Society for Heart and Lung Transplantation in Orlando – GlobeNewswire” on April 04, 2019, also Nasdaq.com with their article: “Hunt Companies Finance Trust, Inc. (HCFT) Ex-Dividend Date Scheduled for March 28, 2019 – Nasdaq” published on March 27, 2019, Seekingalpha.com published: “Stocks To Watch: FOMC, Streaming Wars And JEDI In Focus – Seeking Alpha” on October 26, 2019. More interesting news about TransMedics Group, Inc. (NASDAQ:TMDX) were released by: Globenewswire.com and their article: “TransMedics Announces Pricing of Upsized Initial Public Offering – GlobeNewswire” published on May 01, 2019 as well as Fool.com‘s news article titled: “Is This Organ Transplantation Specialist the Next Great Growth Stock? – The Motley Fool” with publication date: November 10, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.